These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21235090)

  • 1. [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].
    Ito Y
    Gan To Kagaku Ryoho; 2010 Dec; 37(13):2845-9. PubMed ID: 21235090
    [No Abstract]   [Full Text] [Related]  

  • 2. HER2 targeted therapy in breast cancer...beyond Herceptin.
    Pal SK; Pegram M
    Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in HER2-positive breast cancer.
    Sledge GW
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):98-100. PubMed ID: 18347559
    [No Abstract]   [Full Text] [Related]  

  • 4. [Her2 positive breast cancer: practices].
    Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
    Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
    Yamashita T; Iwata K
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
    Reed SD; Schulman KA
    Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
    [No Abstract]   [Full Text] [Related]  

  • 7. Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working?
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):48a-48b. PubMed ID: 19856610
    [No Abstract]   [Full Text] [Related]  

  • 8. Information for patients. HER2: what you need to know.
    Oncology (Williston Park); 2009 Jul; 23(8 Suppl):48a-48b. PubMed ID: 19860043
    [No Abstract]   [Full Text] [Related]  

  • 9. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 as a cancer stem-cell target.
    Roesler R; Cornelio DB; Abujamra AL; Schwartsmann G
    Lancet Oncol; 2010 Mar; 11(3):225-6. PubMed ID: 20202610
    [No Abstract]   [Full Text] [Related]  

  • 11. HER2-positive breast cancer: beyond trastuzumab.
    Murphy CG; Fornier M
    Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 13. Personalised cancer management: closer, but not here yet.
    Piccart M
    Ann Oncol; 2013 Aug; 24(8):1951-5. PubMed ID: 23878113
    [No Abstract]   [Full Text] [Related]  

  • 14. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibodies as molecular target-based therapy: trastuzumab.
    Tokuda Y
    Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2).
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):237. PubMed ID: 16224413
    [No Abstract]   [Full Text] [Related]  

  • 17. [Novel targeting therapy concept for breast cancer treatment].
    Toi M
    Nihon Yakurigaku Zasshi; 2008 Sep; 132(3):177-9. PubMed ID: 18787301
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.